December 2023 Pulmonary Case of the Month: A Budding Pneumonia

Ishan A. Patel, MD¹

Sarah Medrek, MD¹

Michael Reyes, MD²

Brannon Raney, MD³

Section of ¹Pulmonary, Critical Care, and Sleep Medicine, ²Pathology, and ³Infectious Disease

VA Albuquerque Health System

Albuquerque, NM USA

History of Present Illness

A 70-year-old man with a history of seropositive rheumatoid arthritis previously well controlled on hydroxychloroquine, methotrexate, and adalimumab was admitted to the hospital with 3 weeks of progressively worsening fatigue, night sweats, chills, and malaise. He did not describe new or worsening cough, shortness of breath, or sputum production. On the day of admission, he had intense nausea and vomiting.

PMH, SH, and FH

Prior to this admission, he was followed in Pulmonary Clinic for asymptomatic mild basilar fibrosis thought to be related to his rheumatoid arthritis and paraseptal emphysema related to prior smoking which was largely stable and unchanged over the previous two years. Previously, he smoked cigarettes at ½ pack per day for about 30 years and quit about 15 years ago. He denied any recent travel and was retired from the last 15 years from being a meat butcher. FH is noncontributory.

Physical Examination

On examination the day after admission from the ER, the patient’s temperature was 37.6C. His pulse was 79 bpm, blood pressure was 142/65 mmHg, and pulse oximetry revealed a saturation of 92% with 2 LPM nasal cannula of O2. He appeared generally weak, but alert. Pulmonary exam was unrevealing as was cardiac exam. He did not have cyanosis, clubbing, delayed capillary refill, or peripheral edema.

Laboratory

Initial blood work showed a WBC count of 7500/µL, hemoglobin level of 9.6 gm/dl, serum blood urea nitrogen of 36 gm/dl, serum creatinine of 2.49 g/dl, and serum calcium that was elevated at 12.3 mg/dl. A T-spot was obtained and was negative. Blood and sputum cultures were obtained and negative.

Radiography

Figure 1. Admission portable chest x-ray in the emergency department. To view Figure 1 in an enlarged, separate window click here.

The patient has a history of rheumatoid arthritis (RA). Which of the following patterns of interstitial lung disease (ILD) is most common in patients with RA? (Click on the correct answer to be directed to the second of seven pages)

1. Acute eosinophilic pneumonia
2. Lymphocytic interstitial pneumonitis
3. Non-specific interstitial pneumonia
4. Organizing pneumonitis
5. Usual interstitial pneumonitis

Cite as: Patel IA, Medrek SK, Reyes MD, Raney BL. December 2023 Pulmonary Case of the Month: A Budding Pneumonia. Southwest J Pulm Crit Care Sleep. 2023;27(6):62-66. doi: https://doi.org/10.13175/swjpccs048-23 PDF

July 2018 Pulmonary Case of the Month

Anjuli M. Brighton, MB, BCh, BAO

Mayo Clinic Arizona

Scottsdale, AZ USA

Pulmonary Case of the Month CME Information

Completion of an evaluation form is required to receive credit and a link is provided on the last page of the activity. 

0.25 AMA PRA Category 1 Credit(s)™

Estimated time to complete this activity: 0.25 hours

Lead Author(s): Anjuli M. Brighton, MB. All Faculty, CME Planning Committee Members, and the CME Office Reviewers have disclosed that they do not have any relevant financial relationships with commercial interests that would constitute a conflict of interest concerning this CME activity.

Learning Objectives: As a result of completing this activity, participants will be better able to:

1. Interpret and identify clinical practices supported by the highest quality available evidence.
2. Establish the optimal evaluation leading to a correct diagnosis for patients with pulmonary, critical care and sleep disorders.
3. Translate the most current clinical information into the delivery of high quality care for patients.
4. Integrate new treatment options for patients with pulmonary, critical care and sleep related disorders.

Learning Format: Case-based, interactive online course, including mandatory assessment questions (number of questions varies by case). Please also read the Technical Requirements.

CME Sponsor: University of Arizona College of Medicine at Banner University Medical Center Tucson

Current Approval Period: January 1, 2017-December 31, 2018

Financial Support Received: None

History of Present Illness

An 81-year-old gentleman was admitted for syncope. He had felt unwell for one month. His recent illness started with the “flu”. He had lingering productive cough, low volume hemoptysis and felt very fatigued. After a coughing episode he apparently lost consciousness and was taken to the emergency department.

Past Medical History, Social History and Family History

He has a past medical history of hypertension, glaucoma, diverticulosis and COPD. He was taking only antihypertensives including a diuretic. He has a 30 pack-year history of smoking but quit 10 years ago.

Physical Examination

• Normotensive
• Tachypneic
• SpO2 96% on 2L NC
• Afebrile
• Diffuse wheezing, diminished at L base
• Irregularly irregular heart rate

Which of the following are indicated at this time? (Click on the correct answer to be directed to the second of six pages)

1. Chest x-ray
2. Complete blood count (CBC)
3. Electrocardiogram (EKG)
4. 1 and 3
5. All of the above

Cite as: Brighton AM. July 2018 pulmonary case of the month. Southwest J Pulm Crit Care. 2018;17(1):1-6. doi: https://doi.org/10.13175/swjpcc073-18 PDF 

May 2018 Pulmonary Case of the Month

Kenneth K. Sakata, MD

Department of Pulmonary Medicine

Mayo Clinic Arizona

Scottsdale, AZ USA

History of Present Illness

A 70-year-old man was referred because of new anemia and a heme-positive stool. Esophagogastroduodenoscopy (EGD) was performed which revealed gastritis. Ascites developed and a chest x-ray noted a left pleural effusion. He was managed with weekly high-volume thoracentesis and paracentesis. He was referred to pulmonary medicine.

Past Medical History, Social History and Family History

He has a history of coronary artery disease having undergone coronary bypass grafting in 2016. He also has type 2 diabetes mellitus managed by diet and recently diagnosed orthostasis. He smokes about ½ pack of cigarettes per day but does not drink alcohol. He denies any inhalational exposures. He is Native American and works as a judge. There is no family history of any similar disorders.

Physical Examination

• No acute distress
• Slight bruise to left eye
• No lymphadenopathy
• Decreased breath sounds on left
• Protuberant distended abdomen
• Significant left leg edema
• Discoloration of a few nails

A point of contact ultrasound is performed (Figure 1).

Figure 1. Image from the point of contact ultrasound.

What should be done next? (Click on the correct answer to proceed to the second of seven pages)

1. Needle biopsy of pleural mass
2. Thoracentesis
3. Thoracic surgery consultation for video-assisted thorascopic surgery (VATS)
4. 1 and 3
5. All of the above

Cite as: Sakata KK. May 2018 pulmonary case of the month. Southwest J Pulm Crit Care. 2018;16(5):237-44. doi: https://doi.org/10.13175/swjpcc059-18 PDF 

Giant Cell Myocarditis: A Case Report and Review of the Literature

Nathan Spence, MD

Karen Niehaus, MD

Leonardo Macias, MD

Bart Cox, MD

University of New Mexico Hospital

Albuquerque, New Mexico, United States

Introduction 

First described by Saltykow in 1905 (1), Giant cell myocarditis (GCM) is a rare but highly lethal disease. Until the 1980s the diagnosis of GCM was determined at autopsy (2). It often affects young patients (mean age of 42.6 + 12.7 years),  and appears to occur in men and women equally. The occurrence of GCM in minority patients has not been previously described (3). The most common presenting symptom is heart failure (75%), though ventricular tachycardia (14%), chest pain with ECG findings of acute myocardial infarction (6%) and complete heart block (5%) may also occur. Treatment often involves an immunosuppressive regimen as a bridge to heart transplantation. The prevalence of GCM is known primarily from autopsy studies (i.e., 0.051% in India, 0.007% in England,  and 0.023% in Japan) (4-6). In the largest GCM observational study yet published, the rate of death or cardiac transplantation was 89 percent, with a median survival of 5.5 months from the onset of symptoms to the time of death or transplantation (3). Few cases with the successful treatment of GCM have been reported (7). Here we describe a case of GCM in a Hispanic female, the first to our knowledge, in which immediate diagnosis and initiation of an immunosuppressive regimen led to a favorable hospital course, whereby she was clinically stabilized and able to be transferred for transplant evaluation.

Case

A 56-year-old Hispanic female with a past medical history significant only for hypertension presented to our emergency department for evaluation of a non-productive cough over the last 3 days, which was associated with a headache, runny nose, myalgias, nausea, vomiting, chest pain, increased dyspnea on exertion, and lower extremity edema. On initial evaluation, heart rate was 86, blood pressure was 131/84, temperature was 37.4 degrees Celsius, oxygen saturation 96% on room air. Physical exam revealed a patient in moderate distress, a pericardial friction rub, clear lungs, and trace lower extremity edema. Laboratory testing revealed a leukocytosis of 12,800/mm³ (normal < 10,600/mm³), troponin I of 3.020 ng/mL (normal < 0.06 ng/mL), N-Terminal-Pro-BNP of 9,775 pg/mL (normal < 125 pg/mL), elevated ESR of 43 mm/hr (normal < 15mm/hr), elevated CRP of 3.6mg/dL (normal < 1 mg/dL), and a mild eosinophilia of 6% (normal < 5%).  Respiratory viral panel was negative. Chest X-Ray revealed a globular cardiac silhouette without definite evidence of congestion. Twelve-lead electrocardiogram revealed normal sinus rhythm with a new left bundle branch block. Cardiac catheterization revealed no significant coronary stenosis, with a left ventricular end diastolic pressure (LVEDP) of 22 mmHg. Upon admission to the floor, diuresis and titration of guideline based medications for dilated cardiomyopathy were begun, but were promptly discontinued due to development of hypotension. Transthoracic echocardiography (TTE) displayed severe hypokinesis of the basal inferoseptum and inferior wall of the left ventricle. Estimated ejection fraction was 35%, with mild to moderate mitral regurgitation. Blood pressure stabilized on day 2 of admission. Cardiac MR (CMR) with gadolinium was ordered, which did not show definite myocardial delayed enhancement (i.e., no evidence of infarction, myocarditis. See Figure 1).

Figure 1 Cardiac Magnetic Resonance Imaging. (A) Two chamber delayed post-gadolinium inversion recovery view. (B) Two chamber delayed post-gadolinium phase sensitive inversion recovery view.

On day 3 of hospitalization, the patient suddenly developed complete heart block, became hypotensive and confused. As a result, a temporary venous pacemaker (TVP) was placed, and endomyocardial biopsy (EMB) was performed. Five specimens were obtained. Pulmonary capillary wedge pressure was measured at 32 mmHg, with a Fick cardiac output 3.01 L/min and cardiac index of 1.77 L/min/m². Due to persistent hypotension in the cath lab, a dopamine drip was begun, a Swan-Ganz catheter was placed, and the patient was transferred to the Medical Intensive Care Unit for further hemodynamic monitoring and treatment. That afternoon, GCM was diagnosed by pathology (see Figure 2).

Figure 2 Pathology. (A) Infiltration of cardiac muscle tissue by an inflammatory infiltrate. (B) Massive myocyte necrosis with giant cells among the inflammatory infiltrate. (C) Rare eosinophils are seen among the inflammatory infiltrate. (D) Giant cell among the inflammatory infiltrate.

An immunosuppressive regimen of corticosteroids, azathioprine,  and cyclosporine was promptly initiated. Thereafter, over the course of 3 days, clinical symptoms  and hemodynamics improved significantly. TVP was removed, inotropic support was weaned off, and ACE inhibitor and diuretics were titrated. Beta-blockers were withheld out of concern for recent complete heart block and use of inotropic support. On hospital day 10, the patient was transferred, in stable condition, to be evaluated for heart transplantation, and/or mechanical circulatory support. At the outside center, she had an ICD placed for primary prevention, was maintained on the three drug immunosuppression regimen, continued to do well clinically, and was listed for transplant.

Discussion

Several autoimmune disorders have been associated with GCM, which include inflammatory bowel disease, thyroiditis, and thymoma (8). Our patient did not have a history of autoimmune disease, and the laboratory tests to detect such during her hospitalization were negative. Evidence suggests that GCM is an autoimmune disorder dependent on CD4-positive T lymphocytes and anti-myosin autoantibodies (8). Early diagnosis leading to appropriate treatment, as in our case, appears to be imperative for a favorable clinical outcome. Treatment with a combination of immunosuppressives has been shown to improve survival, compared with those not receiving immunosuppressive regimens (12.3 months vs. 3.0 months, p=0.001) (3). If patients live long enough to receive heart transplantation, longer term survival is possible. For that reason, it is a Class I (level of evidence B) guideline recommendation to perform EMB in the setting of unexplained, new-onset heart failure of < 2 weeks' duration associated with a normal sized or dilated left ventricle in addition to hemodynamic compromise (9). The sensitivity of EMB for GCM is 80% to 85% in subjects who subsequently die or undergo heart transplantation (2). Therefore, in the appropriate clinical setting, EMB may drastically alter treatment and provide important prognostic information. The pathological hallmark of GCM is the presence of multinucleated giant cells and a lymphocytic inflammatory infiltrate, associated with myocyte necrosis (10-12). CMR may display delayed myocardial enhancement to support the diagnosis of myocarditis, though a non-diagnostic study, as in our case, does not rule it out.   

We encountered, to our knowledge, the first case of GCM in a patient of Hispanic ethnicity, who presented with the classic associated symptoms of heart failure, hemodynamic collapse, and complete heart block, and whose clinical course was favorably improved by early diagnosis and initiation of an immunosuppressive regimen. CMR did not identify myocarditis. However, this case illustrates the importance of including GCM in the differential diagnosis when a patient presents with suggestive clinical features and is not responding to current evidence based treatment for acute decompensated heart failure.

References

1. Saltykow S. Uber Diffuse Myokarditis. Virchows Archiv fur Pathologische Anatomie. 1905;182:1-39. [CrossRef]
2. Shields RC, Tazelaar HD, Berry GJ, Cooper LT. The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail. 2002;8:74-88. [CrossRef] [PubMed] 
3. Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis - natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336:1860-6.[CrossRef] [PubMed]
4. Vaideeswar P, Cooper L. Giant cell myocarditis: clinical and pathological disease characteristics in an indian population. Cardiovasc Pathol. 2013;22:70-4. [CrossRef] [PubMed]  
5. Whitehead R. Isolated myocarditis. Brit Heart J 1965;27:220-30. [CrossRef] [PubMed]
6. Okada R, Wakafuji S. Myocarditis in autopsy. Heart Vessels 1985; Suppl 1:23-9. [CrossRef]
7. Desjardins V, Pelletier G, Leung TK, Waters D. Successful treatment of severe heart failure caused by idiopathic giant cell myocarditis. Can J Cardiol. 1992;8:788-92. [PubMed] 
8. Cooper L, ElAmm C. Giant Cell Myocarditis: Diagnosis and treatment. Herz. 2012;37:632-6. [CrossRef] [PubMed] 
9. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. A scientific statement from the American heart association, the American college of cardiology, and the European society of cardiology. J Am Coll Cardiol. 2007;50(19):1914-31. [CrossRef] [PubMed] 
10. Davies M, Pomerance A, Teare R. Idiopathic giant cell myocarditis - a distinctive clinico-pathological entity. Br Heart J. 1975;37:192-5. [CrossRef] [PubMed] 
11. Davidoff R, Palacios I, Southern J, Fallon JT, Newell J, Dec GW. Giant cell versus lymphocytic myocarditis. A comparison of their clinical features and long-term outcomes. Circulation. 1991;83:953-61. [CrossRef] [PubMed] 
12. Ren H, Poston RS Jr, Hruban RH, Baumgartner WA, Baughman KL, Hutchins GM. Long survival with giant cell myocarditis. Mod Pathol. 1993;6:402-7. [PubMed] 

Reference as: Spence N, Niehaus K, Macias L, Cox B. Giant cell myocarditis: a case report and review of the literature. Southwest J Pulm Crit Care. 2014;8(4):247-51. doi: http://dx.doi.org/10.13175/swjpcc052-14 PDF

March 2013 Pulmonary Case of the Month: Don’t Rein Me In

Robert W. Viggiano, MD

Michael B. Gotway, MD

Departments of Pulmonary Medicine and Radiology

Mayo Clinic Arizona

Scottsdale, AZ

History of Present Illness

A 70 year old man was referred for a pleural effusion. The patient had pitting edema of the lower extremities noted in March, 2013. At that time a myocardial perfusion study and an echocardiogram were interpreted as being normal with an ejection fraction of 55%. His primary care physician stopped the amlodipine he was taking for hypertension and his edema resolved. However, the amlodipine was restarted a few weeks later for blood pressure control.

PMH, SH, FH

He has a past medical history of hypertension and asthma. He was diagnosed with prostrate cancer in mid 2012. At that time a CT scan of his abdomen/pelvis and a MRI of his pelvis were negative for metastatic disease. He underwent robot assisted radical prostatectomy and bilateral pelvic lymph node dissection in August 2012. His final diagnosis was Gleason 4+5 disease present throughout the prostate with focal extraprostatic extension and lymphovascular and perineural invasion and invasion of right seminal vesicle. He was staged T 3B.

Present medications

• Amlodipine 5 mg at bedtime
• Omelsartan (Benicar®) 40 mg/day
• Salmeterol/fluticasone (Advair®) 100/50 1 puff twice a day
• Clonazepam 0.5 mg twice a day
• Lycopene 10 mg daily

He has a 10 year smoking history but no alcohol or drug use.

Family history is unremarkable.

Physical Examination

Vital signs: Normal

Lungs: Decreased breath sounds in both lung bases

Heart: Elevated JVP; Normal S1 and S2

Abdomen: Negative

Extremities: 2-3+ pitting edema

Laboratory

• CBC: normal
• Electrolytes: normal
• Serum creatinine: 1.0 mg/dL
• Total protein: 6.8 g/dL
• Albumin: 4.3 g/dL
• NT-pro brain naturetic peptide (BNP): 255 pg/ml

Radiography

Chest x-ray is shown in figure 1.

Figure 1. PA (panel A) and lateral (panel B) chest radiography.

Which of the following is false?

1. The patient’s chest x-ray shows bilateral pleural effusions right larger than left
2. A NT-pro BNP 255 pg/ml makes heart failure an unlikely diagnosis
3. His pleural effusion is most likely due to metastatic prostate cancer
4. A normal heart size on chest x-ray excludes heart failure
5. A normal echocardiogram excludes heart failure

Reference as: Viggiano RW, Gotway MB. March 2013 pulmonary case of the month: don't rein me in. Soutwest J Pulm Crit Care. 2013;6(3):93-102. PDF